報價延遲最少15分鐘:2026/08/25 17:37 EDT
盤後時段
|
||||
|
348.48 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
348.48
|
|
|
| 價值評估 |
|
盈利(現時/預測)
7.81/9.73
|
|
企業價值
25.16B
|
| 資產負債 |
|
每股賬面淨值
42.49
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
3.07B
|
|
每股收益
41.58
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States. |
